191 related articles for article (PubMed ID: 20595807)
21. Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models.
Peng X; Hou P; Chen Y; Dai Y; Ji Y; Shen Y; Su Y; Liu B; Wang Y; Sun D; Jiang Y; Zha C; Xie Z; Ding J; Geng M; Ai J
J Exp Clin Cancer Res; 2019 Aug; 38(1):372. PubMed ID: 31438996
[TBL] [Abstract][Full Text] [Related]
22. Fibroblast growth factor receptor signaling is essential for normal mammary gland development and stem cell function.
Pond AC; Bin X; Batts T; Roarty K; Hilsenbeck S; Rosen JM
Stem Cells; 2013 Jan; 31(1):178-89. PubMed ID: 23097355
[TBL] [Abstract][Full Text] [Related]
23. Knockdown of Eag1 Expression by RNA Interference Increases Chemosensitivity to Cisplatin in Ovarian Cancer Cells.
Hui C; Lan Z; Yue-li L; Li-lin H; Li-lin H
Reprod Sci; 2015 Dec; 22(12):1618-26. PubMed ID: 26079730
[TBL] [Abstract][Full Text] [Related]
24. Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells.
Villedieu M; Louis MH; Dutoit S; Brotin E; Lincet H; Duigou F; Staedel C; Gauduchon P; Poulain L
Gynecol Oncol; 2007 Apr; 105(1):31-44. PubMed ID: 17275076
[TBL] [Abstract][Full Text] [Related]
25. Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.
Dienstmann R; Rodon J; Prat A; Perez-Garcia J; Adamo B; Felip E; Cortes J; Iafrate AJ; Nuciforo P; Tabernero J
Ann Oncol; 2014 Mar; 25(3):552-563. PubMed ID: 24265351
[TBL] [Abstract][Full Text] [Related]
26. FOLR1 increases sensitivity to cisplatin treatment in ovarian cancer cells.
Huang MJ; Zhang W; Wang Q; Yang ZJ; Liao SB; Li L
J Ovarian Res; 2018 Feb; 11(1):15. PubMed ID: 29433550
[TBL] [Abstract][Full Text] [Related]
27. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation.
Wang H; Fang L; Jiang J; Kuang Y; Wang B; Shang X; Han P; Li Y; Liu M; Zhang Z; Li P
Cell Death Dis; 2018 Oct; 9(11):1103. PubMed ID: 30375398
[TBL] [Abstract][Full Text] [Related]
28. Trichlorobenzene-substituted azaaryl compounds as novel FGFR inhibitors exhibiting potent antitumor activity in bladder cancer cells in vitro and in vivo.
Chen CH; Liu YM; Pan SL; Liu YR; Liou JP; Yen Y
Oncotarget; 2016 May; 7(18):26374-87. PubMed ID: 27029060
[TBL] [Abstract][Full Text] [Related]
29. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells.
Konecny GE; Kolarova T; O'Brien NA; Winterhoff B; Yang G; Qi J; Qi Z; Venkatesan N; Ayala R; Luo T; Finn RS; Kristof J; Galderisi C; Porta DG; Anderson L; Shi MM; Yovine A; Slamon DJ
Mol Cancer Ther; 2013 May; 12(5):632-42. PubMed ID: 23443805
[TBL] [Abstract][Full Text] [Related]
30. The roles of FGF signaling in germ cell migration in the mouse.
Takeuchi Y; Molyneaux K; Runyan C; Schaible K; Wylie C
Development; 2005 Dec; 132(24):5399-409. PubMed ID: 16291796
[TBL] [Abstract][Full Text] [Related]
31. INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models.
Liu PCC; Koblish H; Wu L; Bowman K; Diamond S; DiMatteo D; Zhang Y; Hansbury M; Rupar M; Wen X; Collier P; Feldman P; Klabe R; Burke KA; Soloviev M; Gardiner C; He X; Volgina A; Covington M; Ruggeri B; Wynn R; Burn TC; Scherle P; Yeleswaram S; Yao W; Huber R; Hollis G
PLoS One; 2020; 15(4):e0231877. PubMed ID: 32315352
[TBL] [Abstract][Full Text] [Related]
32. Targeting the heparin-binding domain of fibroblast growth factor receptor 1 as a potential cancer therapy.
Ling L; Tan SK; Goh TH; Cheung E; Nurcombe V; van Wijnen AJ; Cool SM
Mol Cancer; 2015 Jul; 14():136. PubMed ID: 26201468
[TBL] [Abstract][Full Text] [Related]
33. Emodin regulating excision repair cross-complementation group 1 through fibroblast growth factor receptor 2 signaling.
Chen G; Qiu H; Ke SD; Hu SM; Yu SY; Zou SQ
World J Gastroenterol; 2013 Apr; 19(16):2481-91. PubMed ID: 23674849
[TBL] [Abstract][Full Text] [Related]
34. TRIAP1 Inhibition Activates the Cytochrome c/Apaf-1/Caspase-9 Signaling Pathway to Enhance Human Ovarian Cancer Sensitivity to Cisplatin.
Zhang TM
Chemotherapy; 2019; 64(3):119-128. PubMed ID: 31661694
[TBL] [Abstract][Full Text] [Related]
35. Long Non-coding RNA CCAT1 Sponges miR-454 to Promote Chemoresistance of Ovarian Cancer Cells to Cisplatin by Regulation of Surviving.
Wang DY; Li N; Cui YL
Cancer Res Treat; 2020 Jul; 52(3):798-814. PubMed ID: 32124583
[TBL] [Abstract][Full Text] [Related]
36. FGFR1-4 RNA-Based Gene Alteration and Expression Analysis in Squamous Non-Small Cell Lung Cancer.
Moes-Sosnowska J; Skupinska M; Lechowicz U; Szczepulska-Wojcik E; Skronska P; Rozy A; Stepniewska A; Langfort R; Rudzinski P; Orlowski T; Popiel D; Stanczak A; Wieczorek M; Chorostowska-Wynimko J
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142417
[TBL] [Abstract][Full Text] [Related]
37. [Effects of survivin siRNA on growth, apoptosis and chemosensitivity of ovarian cancer cells SKOV3/DDP].
Zhang X; Li N; Wang YH; Huang Y; Xu NZ; Wu LY
Zhonghua Zhong Liu Za Zhi; 2009 Mar; 31(3):174-7. PubMed ID: 19615253
[TBL] [Abstract][Full Text] [Related]
38. Keratinocyte growth factor binding to fibroblast growth factor receptor 2-IIIb promotes epithelial ovarian cancer cell proliferation and invasion.
Wu J; Han W; Yang W; Liu H; Li C; Guo L; Jin Y; Zhang R; Chen H
J Cancer Res Ther; 2018 Jun; 14(Supplement):S347-S353. PubMed ID: 29970688
[TBL] [Abstract][Full Text] [Related]
39. Lentivirus-Mediated RNAi silencing targeting ERCC1 reverses cisplatin resistance in cisplatin-resistant ovarian carcinoma cell line.
Du P; Zhang X; Liu H; Chen L
DNA Cell Biol; 2015 Jul; 34(7):497-502. PubMed ID: 25941922
[TBL] [Abstract][Full Text] [Related]
40. Anti-Cancer Effect of Cordycepin on FGF9-Induced Testicular Tumorigenesis.
Chang MM; Hong SY; Yang SH; Wu CC; Wang CY; Huang BM
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33172093
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]